Recent updates on the development of ganetespib as a Hsp90 inhibitor

P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).

(2012) K Jhaveri et al.   CANCER RESEARCH

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

(2010) Mikko Taipale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines

(2009) Jennifer K. McCleese et al.   INTERNATIONAL JOURNAL OF CANCER

Heat Shock Protein 90: Inhibitors in Clinical Trials

(2009) Marco A. Biamonte et al.   JOURNAL OF MEDICINAL CHEMISTRY

Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase

(2009) E. S. Ehrlich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

(2008) E. I. Heath et al.   CLINICAL CANCER RESEARCH

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

(2008) Tzu-Yin Lin et al.   EXPERIMENTAL HEMATOLOGY